Pharmacoeconomics of immunoglobulins in primary immunodeficiency

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 9, Issue 4, 2009, Pages 375-386

  Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cost; Cost effectiveness; Effectiveness; Immunoglobulins; Intravenous; Off label use; Primary immunodeficiency; Subcutaneous; Supply

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; PLACEBO; IMMUNOLOGIC FACTOR;

ARTICLE; B LYMPHOCYTE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; DISEASE PREDISPOSITION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; HEALTH CARE SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; OFF LABEL DRUG USE; QUALITY OF LIFE; SUBSTITUTION THERAPY; TREATMENT INDICATION; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG LABELING; ECONOMICS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; PHARMACOECONOMICS; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG LABELING; ECONOMICS, PHARMACEUTICAL; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS;

EID: 70350445985     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.09.37     Document Type: Article

References (26)

1. Membe SK, Ho C, Cimon K, Morrison A, Kanani A, Roifman CM. Economic assessment of different modalities of immunoglobulin replacement therapy. Immunol. Allergy Clin. North Am. 28(4), 861-874 (2008) ••Comprehensive and well-designed economic evaluation of home-based subcutaneous immunoglobulin, hospital-based intravenous immunoglobulin and home-based intravenous immunoglobulin.
2. Durandy A, Wahn V, Petteway S, Gelfand EW. Immunoglobulin replacement therapy in primary antibody deficiency diseases - maximizing success. Int. Arch. Allergy Immunol. 136(3), 217-229 (2005). (Pubitemid 40529193)
3. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs 21(2), 105-116 (2007). •Literature review of the safety and effectiveness of subcutaneous immunoglobulin therapy in patients suffering from primary immunodeficiency. (Pubitemid 46624555)
4. Hogy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur. J. Health Econ. 6(1), 24-29 (2005). (Pubitemid 40543267)
5. Kallenberg CGM, Laseur M. Cost considerations in choosing an intravenous immunoglobulin preparation. Eur. J. Hosp. Pharm. Pract. 13(2), 6-7 (2007).
6. Kumar A, Teuber SS, Gershwin ME. Intravenous immunoglobulin: striving for appropriate use. Int. Arch. Allergy Immunol. 140(3), 185-198 (2006). •Literature review assessing the use of intravenous immunoglobulins in registered indications and off -label conditions. (Pubitemid 43883131)
7. Liu Z, Albon E, Hyde C. The effectiveness and cost effectiveness of immunoglobulin replacement therapy for primary immunodeficiency and chronic lymphocytic leukaemia: a systematic review and economic evaluation. Department of Public Health and Epidemiology, University of Birmingham, AL, USA (2005).
8. Orange JS, Hossny EM, Weiler CR et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 117(4 Suppl.), S525-S553 (2006).
9. Kallenberg CG. A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency. Clin. Exp. Immunol. 150(3), 437-441 (2007).
10. Mahadevia PJ, Strell J, Kunaprayoon D, Gelfand E. Cost savings from intravenous immunoglobulin manufactured from chromotography/caprylate (Igiv-c) in persons with primary humoral immunodeficiency disorder. Value Health 8(4), 488-494 (2005). ••Trial-based cost-consequence analysis evaluating the use of intravenous immunoglobulins in primary immunodefiency from a societal perspective. (Pubitemid 41726102)
11. Gardulf A, Andersen V, Bjorkander J et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 345(8946), 365-369 (1995).
12. Haddad L, Perrinet M, Parent D et al. Étude comparative du coût du traitement à domicile des immunoglobulines intraveineuses ou sous-cutanées a visée substitutive. Revue Méd. Interne 27(12), 924-926 (2006). •Cost-minimization analysis focusing on intravenous immunoglobulin and subcutaneous immunoglobulin in the home setting.
13. Fasth A, Nystrom J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J. Clin. Immunol. 28(4), 370-378 (2008). •One of the few economic evaluations focusing on quality of life associated with immunoglobulin therapy in primary immunodeficiency.
14. Wiles CM, Brown P, Chapel H et al. Intravenous immunoglobulin in neurological disease: a specialist review. J. Neurol. Neurosurg. Psychiatr. 72, 440-448 (2002). (Pubitemid 34289557)
15. Drummond M, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford, UK (2005).
16. Simoens S. Using the Delphi technique in economic evaluation: time to revisit the oracle? J. Clin. Pharm. Ther. 31(6), 519-522 (2006). (Pubitemid 44813764)
17. Buchacher A, Iberer G. Purification of intravenous immunoglobulin G from human plasma - aspects of yield and virus safety. Biotechnol. J. 1(2), 148-163 (2006).
18. Constantine MM, Thomas W, Whitman L et al. Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group. Transfusion 47(11), 2072-2080 (2007). (Pubitemid 47623964)
19. Pendergrast JM, Sher GD, Callum JL. Changes in intravenous immunoglobulin prescribing patterns during a period of severe product shortages, 1995-2000. Vox Sang. 89(3), 150-160 (2005).
20. Boulis A, Goold S, Ubel PA. Responding to the immunoglobulin shortage: a case study. J. Health Polit. Policy Law 27(6), 977-999 (2002). •In-depth review of immunoglobulin shortage in the USA, its causes and responses. (Pubitemid 36135089)
21. Department of Health and Human Services. Intravenous immunoglobulin: Medicare payment and availability. Department of Health and Human Services. Baltimore, MD, USA (2009).
22. Farrugia A, Poulis P. Intravenous immunoglobulin: regulatory perspectives on use and supply. Transfus. Med. 11(2), 63-74 (2001). (Pubitemid 32455656)
23. Bayry J, Kazatchkine MD, Kaveri SV. Shortage of human intravenous immunoglobulin - reasons and possible solutions. Nat. Clin. Pract. Neurol. 3(3), 120-121 (2007). (Pubitemid 46403934)
24. Provan D, Chapel HM, Sewell WA, O'Shaughnessy D. Prescribing intravenous immunoglobulin: summary of Department of Health guidelines. BMJ 337, a1831 (2008).
25. Chen C, Danekas LH, Ratko TA, Vlasses PH, Matuszewski KA. A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers. Ann. Pharmacother. 34(3), 295-299 (2000). (Pubitemid 30133588)
26. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 46(5), 741-753 (2006).